Arcellx Inc (ACLX) reported its financial results for the third quarter of fiscal 2025, surpassing analyst expectations. The company posted an earnings per share (EPS) of $-0.99, beating the consensus estimate of $-1.08 by $0.09. Revenue remained at $0.0B, aligning with expectations.
The results reflect ongoing operational performance as Arcellx continues to develop innovative immunotherapies for cancer and other incurable diseases. Headquartered in Redwood City, California, Arcellx is a clinical-stage biotechnology firm employing 163 full-time staff. The company is advancing its lead program, anitocabtagene autoleucel, a BCMA-targeting CAR T-cell therapy currently evaluated in pivotal trials for relapsed or refractory multiple myeloma.
The company will host an earnings conference call at a later date to discuss these results further and provide insights into its business performance. Investors are encouraged to review the full earnings release and management commentary for a comprehensive understanding of the quarter's outcomes and future outlook.
Looking ahead, Arcellx is scheduled to report its next earnings on March 16, 2026, with an EPS estimate of $-1.0808 and revenue expected to remain at $0.0B.